Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Oritavancin (Primary)
- Indications Gram-positive infections
- Focus Therapeutic Use
- Sponsors The Medicines Company
- 13 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 13 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.
- 24 May 2017 New trial record